Assessment of the effects of L- and N-Type Ca2+ channel blocking drugs using canine blood-perfused papillary muscle preparations

Tohoku Journal of Experimental Medicine

Volumn 212, Issue 4, 2007, Pages 415-422

  Daitoku, Kazuyuki ^a   Seya, Kazuhiko ^a   Furukawa, Ken Ichi ^a   Motomura, Shigeru ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Developed tension; L type calcium channel; Microdialysis; Myocardial interstitial norepinephrine; N type calcium channel

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; CILNIDIPINE; NICARDIPINE; NORADRENALIN; OMEGA CONOTOXIN GVIA; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; DIHYDROPYRIDINE DERIVATIVE;

ADRENERGIC STIMULATION; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DRUG ACTIVITY; DRUG EFFICACY; ELECTROSTIMULATION; EX VIVO STUDY; HEART PAPILLARY MUSCLE; HEART RIGHT VENTRICLE; INTERSTITIUM; LIQUID CHROMATOGRAPHY; MICRODIALYSIS; MUSCLE CONTRACTION; MUSCLE TONE; NONHUMAN; SYMPATHETIC GANGLION; ANIMAL; DOSE RESPONSE; DRUG EFFECT; HEART MUSCLE; METABOLISM; PHYSIOLOGY;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, N-TYPE; DIHYDROPYRIDINES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; MICRODIALYSIS; MUSCLE CONTRACTION; MYOCARDIUM; NICARDIPINE; NOREPINEPHRINE; OMEGA-CONOTOXIN GVIA; PAPILLARY MUSCLES;

EID: 38449090789     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.212.415     Document Type: Article

References (20)

1. Clasbrummel, B., Osswald, H, & Illes, P. (1989) Inhibition of noradrenaline release by ω-conotoxin GVIA in the rat tail artery. Br. J. Pharmacol., 96, 101-110.
2. Cremers, T.I., Teisman, A.C. & van Gilst, W.H. (1997) Use of microdialysis for monitoring sympathetic and parasympathetic innervation of heart in conscious rats. Am. J. Physiol., 273, H2850-H2856.
3. Daitoku, K., Seya, K. & Motomura, S. (1999) Cilinidipine suppresses DMPP-induced cardiac sympathetic nerve activation in canine blood-perfused papillary muscle. J. Cardiovasc. Pharmacol., 34, Suppl. 4, S81-S84.
4. Elhendy, A. & Porter, T.R. (2005) Assessment of myocardial perfusion with real-time myocardial contrast echocardiography: methodology and clinical applications. J. Nucl. Cardiol., 12, 582-590.
5. Endoh, M., Tamura, K. & Hashimoto, K. (1970) Negative and positive inotropic responses of the blood-perfused canine papillary muscle to acetylcholine. J. Pharmacol. Exp. Ther., 175, 377-387.
6. Esler, M., Jennings, G., Korner, P., Blombery, R, Sacharias, N. & Leonard, P. (1984) Measurement of total and organ-specific norepinephrine kinetics in humans. Am. J. Physiol., 247, E21-28.
7. 2+]i. J. Mol. Cell. Cardiol., 29, 1615-1627.
8. Health Canada (1994) Guideline for industry: Dose response information to support drug registration. ICH Topic E4. Ministry of Public Work and Government Services Canada.
9. 2+ channels in evoked release of norepinephrine from sympathetic neurons. Science, 239, 57-61.
10. Ishikawa, Y. & Homcy, C.J. (1997) The adenylyl cyclases as integrators of transmembrane signal transduction. Circ. Res., 80, 297-304.
11. Minami, J., Ishimitsu, T., Kawano, Y., Numabe, A. & Matsuoka, H. (1998) Comparison of 24-hour blood pressure, heart rate, and autonomic nerve activity in hypertensive patients treated with cilnidipine or nifedipine retard. J. Cardiovasc. Pharmacol., 32, 331-336.
12. Motomura, S., Hagihara, A., Narumi, Y. & Hashimoto, K. (1998) Time course of a new ultrashort-acting β-adrenoceptor-blocking drug, ONO-1101: comparison with those of esmolol and propranolol by using the canine isolated, blood-perfused heart preparations. J. Cardiovasc. Pharmacol., 31, 431-440.
13. H-noradrenaline by dimethylphenylpiperazinium (DMPP) in the rat vas deferens. N-S. Arch. Pharmacol., 341, 43-49.
14. Psaty, B.M., Heckbert, S.R., Koepsell, T.D., Siscovick, D.S., Raghunathan, T.E., Weiss, N.S., Rosendaal, F.R., Lemaitre, R.N., Smith, N.L. & Wahl, P.W. (1995) The risk of myocardial infarction associated with antihypertensive drug therapies. J. Am. Med. Assoc., 274, 620-625.
15. Roth, G.J., Stanford, N. & Majerus, P.W. (1975) Acetylation of prostaglandin synthase by aspirin. Proc. Natl. Acad. Sci. USA, 72, 3073-3076.
16. Schmidt, A. & Wu, K.C. (2006) MRI assessment of myocardial viability. Semin. Ultrasound CT, 27, 11-19.
17. Saya, K., Daitoku, K. & Motomura, S. (999) Norepinephrine measurement in the isolated, blood-perfused papillary muscle of the dog by using ex vivo microdialysis. J. Pharmacol. Toxicol. Method, 42, 149-155.
18. Seya, K., Furukawa, K-I., Yoshida, K., Narita, R. & Motomura, S. (2005) Nifedipine enhances cGMP production through the activation of soluble guanylyl cyclase in rat ventricular papillary muscle. J. Pharm. Pharmacol., 57, 511-514.
19. Yamazaki, T. & Akiyama, T. (1996) Effects of locally administered desipramine on myocardial interstitial norepinephrine levels. J. Autonom. Nerv. Syst., 61, 264-268.
20. Yamamoto, T., Niwa, S., Ohno, S., Onishi, T., Matsueda, H., Koganei, H., Uneyama, H., Fujita, S., Takeda, T., Kito, M., Ono, Y., Saitou, Y., Takahara, A., Iwata, S. & Shoji, M. (2006) Structure-activity relationship study of 1, 4-dihydropyridine derivatives blocking N-type calcium channels. Bioorg. Med. Chem. Lett., 16, 798-802.